Ascentage Pharma Group International announced that the company's novel type 1 drug olverembatinib has been included into the 2022 National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the NRDL), for the indication of T315I-mutant chronic-phase chronic myeloid leukemia (CML-CP) and accelerated-phase CML (CML-AP). The new version of the NRDL will take effect from March 1, 2023 onwards. Developed by Ascentage Pharma with support from the National Major New Drug Discovery and Manufacturing program, olverembatinib is a novel type 1 drug as well as the first and only approved third-generation BCR-ABL inhibitor in China, and it is also the only approved therapy for CML harboring the T315I mutation, with global best-in-class potentials.

Olverembatinib was approved in China in November 2021 and is being jointly commercialized in China by Ascentage Pharma and Innovent Biologics Inc. The inclusion will bolster the accessibility of olverembatinib, allowing more patients with CML to easily and affordably access a novel therapeutic that can help to extend patients' lives and enable them to live a more fulfilling life.